Jason A. Okazaki net worth and biography

Jason Okazaki Biography and Net Worth

Mr. Okazaki has served as Assembly’s Chief Executive Officer and President as well as a member of the Board since January 2023. Mr. Okazaki joined Assembly in 2020 as its Chief Legal and Business Officer and was promoted to President and Chief Operating Officer prior to his promotion to Chief Executive Officer and President. Prior to joining Assembly Bio, he served as Senior Vice President, Legal and Assistant Secretary at Gilead Sciences. During his 14-year career there, he built and led a global legal team supporting operations in the United States, Asia and Latin America, and advised on corporate governance and U.S. Securities and Exchange Commission (SEC) reporting matters. Over this period, he also led the structuring and legal execution efforts for Gilead’s acquisitions, divestitures and strategic collaborations. Prior to Gilead, he was an associate at Skadden, Arps, Slate, Meagher & Flom LLP in the law firm’s mergers and acquisitions and corporate finance practices. Mr. Okazaki earned a BA in Economics from Stanford University and a JD from the UC College of the Law, San Francisco (formerly known as UC Hastings College of the Law).

What is Jason A. Okazaki's net worth?: The estimated net worth of Jason A. Okazaki is at least $426.03 thousand as of March 31st, 2025. Okazaki owns 14,757 shares of Assembly Biosciences stock worth more than $426,035 as of March 26th. This net worth approximation does not reflect any other investments that Okazaki may own. Learn More about Jason A. Okazaki's net worth.
How do I contact Jason A. Okazaki?: The corporate mailing address for Okazaki and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on Jason A. Okazaki's contact information.
Has Jason A. Okazaki been buying or selling shares of Assembly Biosciences?: Jason A. Okazaki has not been actively trading shares of Assembly Biosciences within the last three months. Most recently, Jason A. Okazaki sold 355 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $9.85, for a transaction totalling $3,496.75. Following the completion of the sale, the chief executive officer now directly owns 14,757 shares of the company's stock, valued at $145,356.45. Learn More on Jason A. Okazaki's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes William Delaney (Insider), John McHutchison (CEO), Jason Okazaki (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.
Are insiders buying or selling shares of Assembly Biosciences?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,292 shares worth more than $12,726.20. The most recent insider tranaction occured on March, 31st when insider Jeanette M Bjorkquist sold 180 shares worth more than $1,773.00. Insiders at Assembly Biosciences own 5.3% of the company. Learn More about insider trades at Assembly Biosciences.
Information on this page was last updated on 3/31/2025.

Jason A. Okazaki Insider Trading History at Assembly Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2025	Sell	355	$9.85	$3,496.75	14,757
10/3/2024	Sell	197	$14.81	$2,917.57	14,904
5/23/2024	Sell	549	$14.93	$8,196.57	16,082
4/30/2024	Sell	1,569	$12.71	$19,941.99	16,423
4/1/2024	Sell	354	$13.07	$4,626.78	13,826
3/27/2024	Sell	392	$12.87	$5,045.04	14,180
10/3/2023	Sell	196	$9.60	$1,881.60	14,576
5/23/2023	Sell	546	$12.48	$6,814.08	10,551
3/30/2023	Sell	353	$9.84	$3,473.52	8,181
3/27/2023	Sell	391	$12.24	$4,785.84	8,535
3/30/2022	Sell	105	$26.04	$2,734.20
3/28/2022	Sell	384	$26.88	$10,321.92

Jason A. Okazaki Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $28.87

$28.49

$29.53

50 Day Range

MA: $27.98

$25.39

$29.95

2 Week Range

Now: $28.87

$7.75

$39.71

Volume

65,234 shs

Average Volume

98,192 shs

Market Capitalization

$457.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11